YM BioSciences reports second quarter 2010 operational and financial results
MISSISSAUGA, ON,
"After rigorous evaluation of numerous global in-licensing opportunities, we proposed to merge Cytopia Limited., a clinical-stage, Melbourne-based drug development company, into YM during the second quarter," said
Highlights for the second quarter of Fiscal 2010:
- Signed agreement with Therapure Biopharma, under which it will
formulate and fill nimotuzumab into sterile vials in its aseptic,
GMP-certified, and Health Canada-licensed fill suite in Mississauga,
Canada.
- Utilizing YM's IntelliMab(TM) technology, the collaboration between
the National Research Council of Canada's Biotechnology Research
Institute (NRC-BRI) and YM resulted in a number of antibodies that
bind optimally to HER2/neu-over-expressing breast cancer cells while
minimally binding to HER2 on normal cardiac cells.
- Cytopia Limited commenced enrollment of a Phase I/II trial evaluating
CYT387, a potent, orally-administered JAK1/JAK2 inhibitor that is
currently being conducted at Mayo Clinic in Rochester, MN.
- Results showing that nimotuzumab in combination with metronomic
chemotherapy (in frequent, low doses) in an advanced triple-negative
breast cancer preclinical model is safe and effective, were presented
in a poster at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer
Therapeutics conference in Boston, MA.
- Results for CYT997 demonstrating that when administered
metronomically, CYT997 is able to produce potent vascular disrupting
effects in tumors (colon adenocarcinoma xenograft model), and in
combination with cisplatin dosed weekly leads to enhanced antitumor
effects compared to cisplatin alone, were presented in a poster by
Cytopia Limited at the 2009 AACR-NCI-EORTC Molecular Targets and
Cancer Therapeutics conference in Boston, MA.
- Positive 48-month survival data for nimotuzumab were the subject of
an oral presentation at the American Society for Therapeutic
Radiology and Oncology (ASTRO) 2009 Annual Meeting in Chicago, IL.
The trial was a randomized, four-arm study treating patients with
inoperable, locoregionally-advanced, stage III/IVa head-and-neck
cancer with radiation alone, chemoradiation alone, or radiation or
chemoradiation in combination with nimotuzumab.
- Additional results from a Phase III study in children with glioma,
demonstrating that children and adolescents with this inoperable
cancer were able to stay at home or attend school while undergoing
treatment with nimotuzumab, were presented at the International
Society of Paediatric Oncology (SIOP) in Sao Paulo, Brazil.
Subsequent Event
On
Financial Results (CDN dollars)
Total revenue for the second quarter of fiscal 2010, ended
General and administrative expenses were
Licensing and product development expenses were
Costs associated with development activities for nimotuzumab decreased by
Costs associated with development activities for AeroLEF(R) decreased by
Net loss for the second quarter of fiscal 2010 was
As at
As at
About YM BioSciences
YM BioSciences Inc. is a life sciences product development company. Together with the products from merging the Australian company, Cytopia Limited, into YM, which occurred
Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. Cytopia has two products in clinical development. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 by
This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; that and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
YM BIOSCIENCES INC.
Interim Consolidated Balance Sheets
(Expressed in Canadian dollars, unless otherwise indicated)
-------------------------------------------------------------------------
December 31, June 30,
2009 2009
-------------------------------------------------------------------------
(Unaudited)
Assets
Current assets:
Cash $ 30,728,304 $ 2,337,716
Short-term deposits 5,173,645 39,713,042
Accounts receivable 441,815 564,584
Prepaid expenses 142,024 352,850
-----------------------------------------------------------------------
36,485,788 42,968,192
Property and equipment 80,830 96,876
Intangible assets 2,474,597 3,004,868
-------------------------------------------------------------------------
$ 39,041,215 $ 46,069,936
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable $ 537,272 $ 431,028
Accrued liabilities 930,734 486,723
Deferred revenue 2,553,762 2,549,568
-----------------------------------------------------------------------
4,021,768 3,467,319
Deferred revenue 1,616,168 2,898,292
Shareholders' equity:
Share capital 173,023,140 172,921,153
Contributed surplus 13,510,415 13,035,123
Deficit (153,130,276) (146,251,951)
-----------------------------------------------------------------------
33,403,279 39,704,325
Basis of presentation
Commitments
Subsequent event
-------------------------------------------------------------------------
$ 39,041,215 $ 46,069,936
-------------------------------------------------------------------------
-------------------------------------------------------------------------
YM BIOSCIENCES INC.
Interim Consolidated Statements of Operations and Comprehensive Income
and Deficit
(Expressed in Canadian dollars, unless otherwise indicated)
-------------------------------------------------------------------------
Three months ended Six months ended
December 31, December 31,
2009 2008 2009 2008
-------------------------------------------------------------------------
(Unaudited) (Unaudited)
Out-licensing
revenue $ 697,583 $ 1,832,224 $ 1,425,121 $ 3,047,169
Interest
income 13,174 365,067 32,293 807,688
-------------------------------------------------------------------------
710,757 2,197,291 1,457,414 3,854,857
Expenses:
Licensing
and product
development 2,372,946 4,421,428 4,808,994 8,266,612
General and
adminis-
trative 1,699,330 1,193,209 3,483,762 2,340,587
-----------------------------------------------------------------------
4,072,276 5,614,637 8,292,756 10,607,199
-------------------------------------------------------------------------
Loss before
the undernoted (3,361,519) (3,417,346) (6,835,342) (6,752,342)
Gain (loss) on
foreign
exchange (7,130) 79,684 (33,877) 91,887
Gain (loss) on
short-term
deposits (6,888) 163,277 (9,106) 22,718
Other income - - - 307,140
-------------------------------------------------------------------------
Loss and
comprehensive
loss for the
period (3,375,537) (3,174,385) (6,878,325) (6,330,597)
Deficit,
beginning of
period (149,754,739) (136,338,697) (146,251,951) (133,182,485)
-------------------------------------------------------------------------
Deficit, end
of period $(153,130,276) $(139,513,082) $(153,130,276) $(139,513,082)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Basic and
diluted loss
per common
share $ (0.06) $ (0.06) $ (0.12) $ (0.11)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted
average number
of common
shares
outstanding 55,888,710 55,835,356 55,862,879 55,835,356
Excludes common
shares held in
escrow for
contingent
additional
payment
related to the
acquisition of
Delex
Therapeutics
Inc. 2,380,953 2,380,953 2,380,953 2,380,953
-------------------------------------------------------------------------
-------------------------------------------------------------------------
YM BIOSCIENCES INC.
Interim Consolidated Statements of Cash Flows
(Expressed in Canadian dollars, unless otherwise indicated)
-------------------------------------------------------------------------
Three months ended Six months ended
December 31, December 31,
2009 2008 2009 2008
-------------------------------------------------------------------------
(Unaudited) (Unaudited)
Cash provided
by (used in):
Operating
activities:
Loss for the
period $ (3,375,537) $ (3,174,385) $ (6,878,325) $ (6,330,597)
Items not
involving
cash:
Amortiza-
tion of
property
and
equipment 17,331 18,844 33,583 37,476
Amortiz-
ation of
intangible
assets 265,135 265,136 530,271 530,271
Loss
(gain)on
short-term
deposits 6,888 (163,277) 9,106 (22,718)
Stock-based
compensation 118,046 189,223 514,690 379,556
Change in
non-cash
operating
working
capital:
Accounts
receivable
and
prepaid
expenses 87,560 (191,057) 333,595 (300,897)
Accounts
payable,
accrued
liabili-
ties and
deferred
revenue (722,825) (1,585,637) (727,675) (2,268,645)
-----------------------------------------------------------------------
(3,603,402) (4,641,153) (6,184,755) (7,975,554)
Financing
activities:
Issuance of
common
shares on
exercise of
options 51,165 - 62,589 -
Investing
activities:
Short-term
deposits,
net 25,422 (174,312) 34,530,291 13,025,814
Additions to
property and
equipment (13,974) (2,332) (17,537) (15,036)
----------------------------------------------------------------------
11,448 (176,644) 34,512,754 13,010,778
-------------------------------------------------------------------------
Increase
(decrease) in
cash (3,540,789) (4,817,797) 28,390,588 5,035,224
Cash, beginning
of period 34,269,093 12,972,210 2,337,716 3,119,189
-------------------------------------------------------------------------
Cash, end of
period $ 30,728,304 $ 8,154,413 $ 30,728,304 $ 8,154,413
-------------------------------------------------------------------------
-------------------------------------------------------------------------
%SEDAR: 00004652E
For further information: James Smith, the Equicom Group Inc., Tel. (416) 815-0700 x 229, Email: [email protected]; Thomas Fechtner, the Trout Group LLC, Tel. (646) 378-2931, Email: [email protected]
Share this article